ImmunoGen is an emerging biopharmaceutical company in the oncology sector, focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company’s potent cell-killing agents attached as a “payload”. The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells.

The company’s mission statement is “We exist to interrupt the progress of cancer so cancer can’t interrupt the lives of our patients. This is our purpose. This is why we do what we do”. ImmunoGen’s goal is to give the world a therapy that targets cancer cells where they live, not where you live.


  • Data sharing among internal teams
  • FDA validatable system
  • Low total cost of ownership


  • Discoverant™ and TIBCO® Statistica™
  • MS Excel


  • Organizing data received from CMOs
  • Ease of data transfer with their CMOs
  • Data sharing among internal teams
  • Organizing initial product and process characterization data
  • Low total cost of ownership
  • Part 11 compliant
  • Likelihood of future product enhancements and features
  • Compatible with current and future automation systems